



Financial Tear Sheet

Corporate Profile

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives, all while delivering value to our shareholders.

Linda Lennox
 Vice President, Investor
 Relations & Corporate
 Communications

Phone: 617-498-2846

Email:

lillenox@amagpharma.com

Headquartered in Waltham, Massachusetts, with locations in Tucson, Arizona, and San Bruno, California, our products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. In addition, we help families preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Along with driving organic growth of our products, we seek to leverage our existing commercial infrastructure with additional commercial-stage products in our two current therapeutic areas and may consider late-stage development assets or seek opportunities in new therapeutic areas.

Stock Information

AMAG (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$14.25
Change (%)	▼ 0.15 (1.04%)
Volume	646,447
52 Week Low	\$11.93
Market Cap	\$504,010,259
Rolling EPS	-6.08
PE Ratio	0



Shares Outstanding 35,369,141

Data as of January 16, 2018 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News & Upcoming Events

January 08, 2018

There are currently no events scheduled.

AMAG Pharmaceuticals Announces Preliminary
2017 Financial Results and Provides 2018
Guidance

December 21, 2017

AMAG Pharmaceuticals Awards \$300,000 in Grants
to Further Research in Preterm Birth and Neonatal
Health

December 20, 2017

AMAG Pharmaceuticals to Present at the 36th
Annual J.P. Morgan Healthcare Conference

SEC Filings

Filing Date	Form
January 08, 2018	8-K
December 07, 2017	CT ORDER
December 05, 2017	3
November 30, 2017	8-K